1.Elucidation of the catalytic cycle of ATP hydrolysis by Pgp and role of conserved motifs in the ATP-binding cassette:We are continuing our studies on the catalytic cycle of ATP hydrolysis by Pgp. Based on the thermodynamic and kinetic properties we have identified the E-S and E-P stable reaction intermediates of the Pgp-mediated ATPase reaction. Using this defined framework and the Walker B E556Q/E1201Q double mutant, we can precisely attribute the high to low affinity switch in the transport substrate binding site to the formation of the E-S reaction intermediate. Importantly, the post-hydrolysis E-P state continues to have low affinity for drug-substrate, suggesting that conformational changes that form the E-S complex are coupled to the transport substrate site to do mechanical work. Thus, the formation of the E-S reaction intermediate during a single turnover of the catalytic cycle appears to provide the initial power stroke for movement of drug substrates from the inner leaflet to the outer leaflet of the lipid bilayer. To complement these studies, the data mining, sequence alignment of 18K ABC domains and site-directed mutagenesis approaches are used to assess the role of critical residues in the conserved subdomains in the NBDs in ATP-binding and hydrolysis. We recently described a conserved subdomain of the ABC, which we named the A-loop (Aromatic residue interacting with the Adenine ring of ATP). This aromatic residue, 25 residues upstream of the Walker A motif, is conserved in 85% of ABC proteins. Biochemical and mutagenesis studies demonstrate that this residue is critical for ATP-binding. Homology modeling of the NBDs of Pgp based on the structure of a dimer of the E171Q mutant MJ0796 NBD shows that the tyrosine (Y401 or Y1044) residue stacks against the adenine base of ATP through ?a-?a interactions. 2.Development of synthetic or natural product modulators that inhibit multiple ABC drug transporters:Work from several labs including ours has established that ABCB1, ABCG2 and ABCC1 are the major contributors to the development of MDR and these transporters exhibit significant overlap in substrate specificity. To develop modulator(s) that will inhibit multiple transporters, we screened synthetic compounds from several sources as well as natural products. We found that curcumin isolated from the turmeric powder, which is consumed daily as a spice in many countries, is a potent modulator of all three transporters. Interestingly, curcumin is not very cytotoxic and it is not transported by ABCB1, C1 or G2. In addition to curcumin, tetrahydroxy curcumin, which is a major metabolite of curcumin, was also found to modulate the function of these transporters (these studies were carried out in collaboration with Dr. P. Limtrakul, Chiang Mai University, Thailand). In addition, in collaboration with Dr. Susan Bates (NCI, NIH) we demonstrated that dihydropyridines, which are used in the clinic to treat hypertension, are transport substrates for ABCG2, similar to ABCB1. Thus, both ABCB1 and G2 might be an important determinant for the potency and use of dihydropyridines for the treatment of hypertension. 3.Resolution of three-dimensional structure of human Pgp:The resolution of the three-dimensional structure of Pgp is an ongoing project in collaboration with Dr. Di Xia in the Laboratory of Cell Biology. Currently, we have been able to obtain 10-12 mg pure Pgp/ml using either 1,2-diheptanoyl-sn-glycero-phosphocholine (DHPC) or dodecyl maltoside detergent. In addition to wild-type protein, several mutants including the E556Q/E1201Q double mutant, which is trapped in an E-S pre-hydrolysis transition-like state in the presence of ATP, have also been purified. Similarly, to stabilize the conformation of wild-type protein in the E-S pre-hydrolysis transition state, we have developed conditions including the use of ATP-??-S, which is a non-hydrolyzable analog of ATP.

Agency
National Institute of Health (NIH)
Institute
Division of Basic Sciences - NCI (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC010030-11
Application #
7338278
Study Section
(LCB)
Project Start
Project End
Budget Start
Budget End
Support Year
11
Fiscal Year
2006
Total Cost
Indirect Cost
Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Macalou, S; Robey, R W; Jabor Gozzi, G et al. (2016) The linker region of breast cancer resistance protein ABCG2 is critical for coupling of ATP-dependent drug transport. Cell Mol Life Sci 73:1927-37
Wu, Chung-Pu; Sim, Hong-May; Huang, Yang-Hui et al. (2013) Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells. Biochem Pharmacol 85:325-34
Gillet, Jean-Pierre; Calcagno, Anna Maria; Varma, Sudhir et al. (2012) Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. Clin Cancer Res 18:3197-206
Gillet, Jean-Pierre; Wang, Junbai; Calcagno, Anna Maria et al. (2011) Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. Mol Pharm 8:2080-8
Kannan, Pavitra; Telu, Sanjay; Shukla, Suneet et al. (2011) The ""specific"" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS Chem Neurosci 2:82-9
Sharma, Monika; Manoharlal, Raman; Shukla, Suneet et al. (2009) Curcumin modulates efflux mediated by yeast ABC multidrug transporters and is synergistic with antifungals. Antimicrob Agents Chemother 53:3256-65
Kim, In-Wha; Booth-Genthe, Catherine; Ambudkar, Suresh V (2008) Relationship between drugs and functional activity of various mammalian P-glycoproteins (ABCB1). Mini Rev Med Chem 8:193-200
Wright, Mollie H; Calcagno, Anna Maria; Salcido, Crystal D et al. (2008) Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 10:R10
Robey, Robert W; Shukla, Suneet; Finley, Elizabeth M et al. (2008) Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem Pharmacol 75:1302-12
Shukla, Suneet; Wu, Chung-Pu; Ambudkar, Suresh V (2008) Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Expert Opin Drug Metab Toxicol 4:205-23

Showing the most recent 10 out of 58 publications